{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:53:16Z","timestamp":1791085996504,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,7,11]],"date-time":"2010-07-11T00:00:00Z","timestamp":1278806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The administration of rituximab (RTX)<jats:italic>in vivo<\/jats:italic>results in B-cell depletion, but evidence for multiple mechanisms of action have been reported. Surprisingly, B cell depletion produced a response in patients with polymyositis, which is characterized as a T cell-mediated autoimmune disorder with biopsy findings similar to Miyoshi myopathy (MM). Indeed, in dysferlinopathies, there is evidence of immune system involvement including the presence of muscle inflammation and a down regulation of the complement inhibitory factor, CD55.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two patients were treated with four weekly infusions of RTX 375 mg\/m2. To measure the improvement in muscle strength after treatment, the isometric hand grip maximal voluntary contraction (MVC) was measured by load cell four times during treatment, and again after one year. In order to assess the reproducibility of our grip assessment, we determined the hand MVC analysis in 16 healthy subjects. Moreover, we measured the number of B cells present in patients by flow cytometric analysis during the course of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis of B cell number during the course of treatment showed that CD20- and CD19-positive cells were depleted to 0-0.01%. The decrease in B cells was followed by an improvement in the mobility of the pelvic and shoulder girdles as shown by the MRC%. The MVC values of both patients began at values lower than normal whereas during treatment patients had improved percentage of muscle strength. The strength peak in both patients coincided with the minimum B cell values. There were no severe adverse events associated with an infusion of RTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We consider the increase in muscle strength observed in both treated patients to be a consequence of their treatment with RTX. To our knowledge, these are the first cases of increased muscle strength in patients with MM. Furthermore, the results of this study indicate that B cell depletion with RTX may be useful in the treatment of patients affected by MM, suggesting a possible role for B cells in the pathophysiology of this muscle disorder.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2474-11-157","type":"journal-article","created":{"date-parts":[[2010,7,13]],"date-time":"2010-07-13T06:13:56Z","timestamp":1279001636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy"],"prefix":"10.1186","volume":"11","author":[{"given":"Alberto","family":"Lerario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Cogiamanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Belicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Porretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Torrente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,11]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/1682","volume":"20","author":"J Liu","year":"1998","unstructured":"Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH: Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998, 20: 31-36. 10.1038\/1682.","journal-title":"Nat Genet"},{"issue":"11","key":"903_CR2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1212\/01.WNL.0000068333.43005.12","volume":"60","author":"T Takahashi","year":"2003","unstructured":"Takahashi T, Aoki M, Tateyama M, et al: Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology. 2003, 60 (11): 1799-804.","journal-title":"Neurology"},{"key":"903_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/01.wco.0000175936.23945.b6","volume":"18","author":"Frank L Mastagliaa","year":"2005","unstructured":"Mastagliaa Frank, Lamontc Phillipa, Laingd Nigel: Distal myopathies. Curr Opin Neurol. 2005, 18: 504-510. 10.1097\/01.wco.0000175936.23945.b6.","journal-title":"Curr Opin Neurol"},{"key":"903_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2990.2002.00417.x","volume":"28","author":"M Fanin","year":"2002","unstructured":"Fanin M, Angelini C: Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002, 28: 461-70. 10.1046\/j.1365-2990.2002.00417.x.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"903_CR5","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.4049\/jimmunol.175.9.6219","volume":"175","author":"K Wenzel","year":"2005","unstructured":"Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, Harris CL, Ho M, Schulz H, Hummel O, Hubner N, Osterziel KJ, Spuler S: Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor\/CD55 in dysferlin-deficient muscular dystrophy. J Immunol. 2005, 175 (9): 6219-25.","journal-title":"J Immunol"},{"key":"903_CR6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1468-1331.2007.01958.x","volume":"14","author":"H Hattori","year":"2007","unstructured":"Hattori H, Nagata E, Oya Y, Takahashi T, Aoki M, Ito D, Suzuki N: A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene. European Journal of Neurology. 2007, 14: 1288-1291. 10.1111\/j.1468-1331.2007.01958.x.","journal-title":"European Journal of Neurology"},{"key":"903_CR7","volume-title":"Personal communication at American Academy of Neurology","author":"Marinof","year":"2006","unstructured":"Marinof: Personal communication at American Academy of Neurology. 2006"},{"key":"903_CR8","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME: Rituximab as therapy for refractory Polymyositis and Dermatomyositis. J Rheumatol. 2006, 33: 1021-6.","journal-title":"J Rheumatol"},{"key":"903_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1067\/S0022-3476(03)00382-2","volume":"143","author":"BA Binstadt","year":"2003","unstructured":"Binstadt BA, Caldas AM, Turvey SE, Stone KD, Weinstein HJ, Jackson J, Fuhlbrigge RC, Sundel RP: Rituximab therapy for multistymem autoimmune disease in pediatric patients. J Pediatr. 2003, 143: 598-604. 10.1067\/S0022-3476(03)00382-2.","journal-title":"J Pediatr"},{"key":"903_CR10","doi-asserted-by":"crossref","unstructured":"Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial. Blood. 2008, 111 (12): 10.1182\/blood-2007-10-117671.","DOI":"10.1182\/blood-2007-10-117671"},{"issue":"2","key":"903_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ncprheum0424","volume":"3","author":"RP Taylor","year":"2007","unstructured":"Taylor RP, Lindorfe MA: Drug Insight: the mechanism of action of Rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007, 3 (2): 86-95. 10.1038\/ncprheum0424. Review","journal-title":"Nat Clin Pract Rheumatol"},{"key":"903_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1460-9568.2007.05633.x","volume":"26","author":"F Cogiamanian","year":"2007","unstructured":"Cogiamanian F, Marceglia S, Ardolino G, Barbieri S, Priori A: Improved isometric force endurance after transcranial direct current stimulation over the human motor cortical areas. European Journal of Neuroscience. 2007, 26: 242-249. 10.1111\/j.1460-9568.2007.05633.x.","journal-title":"European Journal of Neuroscience"},{"key":"903_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/mus.880050405","volume":"5","author":"OM Scott","year":"1982","unstructured":"Scott OM, Hyde SA, Goddard C, Dubowitz V: Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle & Nerve. 1982, 5: 291-301.","journal-title":"Muscle & Nerve"},{"issue":"2","key":"903_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD: Rituximab in the Treatment of Dermatomyositis An Open-Label Pilot Study. Arthtitis & rheumatism. 2005, 52 (2): 601-607.","journal-title":"Arthtitis & rheumatism"},{"key":"903_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI20325","volume":"114","author":"Y Torrente","year":"2004","unstructured":"Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D'Antona G, Tonlorenzi R, Porretti L, Gavina M, Mamchaoui K, Pellegrino MA, Furling D, Mouly V, Butler-Browne GS, Bottinelli R, Cossu G, Bresolin N: Human circulating AC133+ stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest. 2004, 114: 182-195.","journal-title":"J Clin Invest"},{"key":"903_CR16","first-page":"66","volume":"26","author":"A Grillo-Lopez","year":"1999","unstructured":"Grillo-Lopez A, et al: Overview of the clinical development of Rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999, 26: 66-73.","journal-title":"Semin Oncol"},{"key":"903_CR17","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman F, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984, 63: 1424-33.","journal-title":"Blood"},{"key":"903_CR18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","volume":"7","author":"DA Einfeld","year":"1988","unstructured":"Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988, 7: 711-7.","journal-title":"EMBO J"},{"key":"903_CR19","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1016\/S0021-9258(18)60461-2","volume":"264","author":"MA Valentine","year":"1989","unstructured":"Valentine MA, Meier KE, Rossie S, Clark EA: Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase. C J Biol Chem. 1989, 264: 11282-7.","journal-title":"C J Biol Chem"},{"key":"903_CR20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","volume":"135","author":"TF Tedder","year":"1985","unstructured":"Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985, 135: 973-9.","journal-title":"J Immunol"},{"key":"903_CR21","first-page":"195","volume":"140","author":"TF Tedder","year":"1990","unstructured":"Tedder TF, Zhou LJ, Bell PD, Frizzell R, Bubien J: The CD20 surface molecule of B lymphocytes functions as a calcium channel. J Cell Biochem. 1990, 140: 195-","journal-title":"J Cell Biochem"},{"issue":"5 Suppl 14","key":"903_CR22","first-page":"79","volume":"26","author":"P McLaughlin","year":"1999","unstructured":"McLaughlin P, Hagemeister FB, Grillo-Lopez AJ: Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999, 26 (5 Suppl 14): 79-87.","journal-title":"Semin Oncol"},{"key":"903_CR23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","volume":"52","author":"TD Levine","year":"1999","unstructured":"Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999, 52: 1701-4.","journal-title":"Neurology"},{"key":"903_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","volume":"74","author":"A Pestronk","year":"2003","unstructured":"Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003, 74: 485-9. 10.1136\/jnnp.74.4.485.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"903_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1042\/bst0300824","volume":"30","author":"JC Edwards","year":"2002","unstructured":"Edwards JC, Leandro MJ, Cambridge G: B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002, 30: 824-8. 10.1042\/BST0300824.","journal-title":"Biochem Soc Trans"},{"key":"903_CR26","first-page":"3659","volume":"48","author":"DA Albert","year":"2003","unstructured":"Albert DA, Khan SR, Stansberry J, Tsai D, Eisenberg RA: A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus. Arthritis Rheum. 2003, 48: 3659-","journal-title":"Arthritis Rheum"},{"issue":"Suppl:ii","key":"903_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ard.62.suppl_2.ii55","volume":"62","author":"T Shaw","year":"2003","unstructured":"Shaw T, Quan J, Totoritis MC: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003, 62 (Suppl:ii): 55-9.","journal-title":"Ann Rheum Dis"},{"key":"903_CR28","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350: 2572-81. 10.1056\/NEJMoa032534.","journal-title":"N Engl J Med"},{"key":"903_CR29","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004, 50: 2580-9. 10.1002\/art.20430.","journal-title":"Arthritis Rheum"},{"key":"903_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63: 803-43. 10.2165\/00003495-200363080-00005.","journal-title":"Drugs"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-11-157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-11-157\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-11-157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-11-157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T21:35:14Z","timestamp":1740260114000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-11-157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,11]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-11-157","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,11]]},"assertion":[{"value":"11 December 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"157"}}